# AdaptHealth Corp. (AHCO) — Financial Analysis

**Exchange:** Nasdaq  
**Coverage as of:** 2026-Q2  
**Updated:** 2026-06-12  
**Tier:** Free primer (step 2 of 19)  
**Sibling pages:** /stocks/AHCO/thesis · /stocks/AHCO/memo

## Financial Snapshot

---
source: coverage-next-full
ticker: AHCO
company: AdaptHealth Corp.
step: 04
title: Financial Quality & Adversarial Sweep
created: 2026-06-11
---

### Step 04 — Financial Quality & Adversarial Sweep: AdaptHealth Corp (AHCO)

#### 1. Statement Quality Assessment

##### Income Statement Adjustments

The three most significant income statement distortions for AHCO:

**Adjustment 1: Patient Equipment Depreciation in COGS (Non-Cash, Structural)**
AHCO includes ~$362M/yr of patient equipment depreciation inside Cost of Revenue. This is a non-cash charge representing the amortization of the company's equipment fleet. While this is technically an operating cost (equipment does wear out and must be replaced), presenting it as COGS systematically understates gross margins versus peers that expense equipment depreciation below the gross profit line. The correct analytical response is to evaluate EBITDA and cash conversion, not GAAP gross profit.

*Adjusted gross margin (removing patient equipment depr. from COGS):*

| FY | Reported Gross Margin | Patient Equip. Depr. (% rev.) | Adjusted Gross Margin |
|----|----------------------|-------------------------------|----------------------|
| 2023 | 19.5% | ~10.9% | ~30.4% |
| 2024 | 20.9% | ~10.5% | ~31.4% |
| 2025 | 18.8% | ~11.1% | ~29.9% |

This adjusted view shows AHCO's actual service margin is in the 30%+ range — competitive with peers once the equipment rental model is properly accounted for [S1].

**Adjustment 2: Goodwill Impairments ($958M, 2023–2025)**
Two non-cash goodwill impairments ($830.8M in FY2023, $128M in FY2025) dominated reported GAAP results in those years but had zero cash impact. These impairments are significant disclosures about acquisition pricing errors (AHCO overpaid for Diabetes Health acquisitions), not operational deterioration. Excluding these charges, operating income was positive in every year [S1].

**Adjustment 3: COGS Reclassification (FY2024)**
AHCO reclassified ~$144.5M of revenue cycle management costs from COGS to G&A in FY2024, restating prior years. This improved reported gross margin by ~450 bps on a like-for-like basis. No impact on operating income, EBITDA, or cash flow — but analysts must apply consistent treatment when comparing gross margins across years [S1].

##### Cash Flow Quality

Operating cash flow has consistently exceeded GAAP net income by a large margin due to the non-cash depreciation add-back:

| FY | GAAP Net Income | Operating CF | CF / Net Income Ratio |
|----|----------------|-------------|----------------------|
| 2023 | ($678.9M) | $480.7M | NM (net loss) |
| 2024 | $90.4M | $541.8M | 6.0x |
| 2025 | ($70.8M) | $601.8M | NM (net loss) |

This is structurally explained and expected for an equipment-rental model. Operating cash flow is the correct earnings proxy [S1].

##### Working Capital

AHCO generates revenue through insurance reimbursement, which creates accounts receivable concentration risk. From 10-K disclosures:
- Accounts receivable days are elevated (healthcare billing lag)
- No unusual increase in DSOs detected between FY2023 and FY2025 *[ESTIMATE: DSOs likely 45–60 days, standard for insurance-billed healthcare]*
- The April 2026 credit facility refinancing ($1.1B, extended to 2031) provides working capital flexibility [S3]

#### 2. Financial Metrics Summary

| Metric | FY2023 | FY2024 | FY2025 |
|--------|--------|--------|--------|
| Revenue | $3,200.2M | $3,261.0M | $3,244.9M |
| Gross Margin | 19.5% | 20.9% | 18.8% |
| EBIT Margin | (18.7%) | 8.1% | 2.8% |
| Adj. EBITDA | $615.2M* | $688.7M | $616.7M |
| Adj. EBITDA Margin | 19.2% | 21.1% | 19.0% |
| Operating CF | $480.7M | $541.8M | $601.8M |
| FCF | $143.2M | $235.7M | $219.4M |
| Net Debt | ~$2.2B | ~$1.9B | ~$1.8B |
| Net Debt / Adj. EBITDA | ~3.6x | ~2.8x | ~2.9x |

*FY2023 Adj. EBITDA = approximate proxy; company-reported figure was $615M range.*

#### 3. Adversarial Research Sweep

*This section reviews publicly available short reports, regulatory actions, lawsuits, and credible negative narratives.*

##### Finding 1: Governance Instability — Three CEO Changes (2022–2024)
Three CEO changes in approximately two years (Luke McGee departed 2022; Suzanne Foster replaced as CEO in mid-2023; Joshua Foster installed as permanent CEO mid-2024) created significant operational instability [S2]. Referral source confidence was reported as disrupted. Management transitions at this frequency signal either strategic disarray or significant cultural dysfunction. *[JUDGMENT: Resolved near-term — Foster has stabilized execution and guided FY2025 FCF above guidance. Bear risk: recurring leadership instability.]*

##### Finding 2: Serial Goodwill Impairments ($958M Total)
Two material goodwill impairments in two years — $830.8M in FY2023 (Diabetes + Wellness segments) and $128M in FY2025 (Diabetes segment) — confirm that management significantly overpaid for acquisitions in the 2020–2021 acquisition binge. Per accounting standards (ASC 350), impairments occur when the estimated recoverable value of a reporting unit falls below its carrying value — meaning the assets are worth less than paid [S1].

**Bull rebuttal:** These are non-cash, backward-looking acknowledgments. The underlying operating businesses continue to generate cash. The impairments are complete (carrying values now reflect a more conservative base).  
**Bear view:** Further impairments possible if Diabetes segment continues to deteriorate.

##### Finding 3: AeroCare Integration Friction
The $1.6B AeroCare acquisition (2021) was ambitious — one of the largest HME deals ever. Integration friction manifested as:
- Margin compression (gross margins declined 2021–2022 during integration)
- Leadership churn
- "One Adapt" platform delays
The AeroCare integration appears substantially complete as of FY2024, with the CEO citing "integration tailwinds" and EBITDA margin recovery [S4].

##### Finding 4: Leverage — Net Debt ~3.0x EBITDA
At ~$1.8B net debt on ~$616M EBITDA, AHCO's leverage is meaningfully above investment-grade thresholds (~2.0–2.5x). If EBITDA were to decline 20–25% (e.g., from a major payor contract loss or competitive bidding shock), leverage would spike to ~3.5–4.0x, creating refinancing risk. The April 2026 refinancing (maturity extended to 2031) eliminates near-term maturity cliff, but the leverage remains a structural vulnerability [S3].

**Bull rebuttal:** FCF of $200M+/yr is being deployed to debt repayment. Net debt has declined $400M+ over 4 years. Trajectory is clearly delevering.

##### Finding 5: Diabetes Segment Structural Decline
The Diabetes segment faces irreversible channel shift as CGM manufacturers move toward pharmacy distribution. This is not a cyclical issue — it represents a permanent loss of the CGM distribution channel for traditional HME providers. AHCO can compete for complex/Type 1 patients where clinical expertise justifies the HME channel, but the mass market (Type 2 CGM users) is moving to retail pharmacy. *[FACT: $128M goodwill impairment in FY2025 explicitly acknowledges this.]*

##### Finding 6: Capitation Actuarial Risk (Novel)
The new nationwide capitation contract is the largest in industry history — and AdaptHealth has limited experience managing actuarial risk at this scale. If actual patient utilization within the capitated population exceeds the budgeted PMPM amount, AdaptHealth absorbs the loss. Prior capitation experience was limited to smaller, regional contracts. *[ESTIMATE: Actuarial loss probability is low-to-moderate in FY2026 given that contract terms were set with utilization data; elevated in FY2027+ if patient health status differs from actuarial assumptions.]*

##### No Short Reports Found
No prominent short-seller research reports specifically targeting AHCO were identified in the search. The stock's decline from ~$40 (2021) to ~$9 (2025) appears driven by fundamental deterioration (governance, impairments) rather than fraud or misrepresentation.

##### Finding 7: Reimbursement Fraud Risk (Sector-Level)
Healthcare services companies are perennial targets for HHS-OIG and DOJ billing fraud investigations. AHCO has a compliance committee and compliance program. No material ongoing investigations were identified in recent 10-K risk factor disclosures. *[ESTIMATE: Standard sector-level risk; no elevated company-specific flag.]*

#### 4. Accounting Quality Summary

| Dimension | Assessment | Notes |
|-----------|-----------|-------|
| Revenue recognition | Clean | Insurance-billed; revenue recognized at point of service/delivery |
| Non-cash charges | Material but disclosed | D&A ~$382M/yr; goodwill impairments disclosed promptly |
| Cash conversion | Strong | OCF consistently exceeds GAAP earnings by large margin |
| Debt structure | Manageable post-refi | Extended to 2031; weighted cost reduced |
| Goodwill/intangibles | Elevated but declining | $2.6B goodwill; being impaired appropriately |
| Segment reporting | Limited granularity | Only approximate segment data publicly available |
| Restatements | Minor | FY2024 COGS reclassification (non-material) |

**Overall financial quality: MODERATE — PASS**
The business is financially transparent. GAAP earnings are distorted by non-cash items but those distortions are well-disclosed and analytically adjustable. The primary financial concern is leverage, not accounting quality.

#### Source Index

| ID | Source |
|----|--------|
| S1 | SEC EDGAR XBRL — `xbrl/xbrl_summary.md` |
| S2 | `industry/competitive_landscape.md`; governance discussion; proxy |
| S3 | AdaptHealth credit facility refinancing; `other/consensus.md` |
| S4 | AdaptHealth FY2024 10-K / FY2025 10-K; `sec_filings/10K_FY2024_summary.md`, `10K_FY2025_summary.md` |

## Deeper Financial Analysis

The fundamental tier ($1.00) adds 8 dimensions not included here:

- Revenue Breakdown — segment revenue, geographic mix, product-line margins
- Financial Trends — QoQ momentum, leading indicators, inflection points
- Balance Sheet — debt structure, dilution risk, working capital dynamics
- Capital Allocation — ROIC, buyback cadence, reinvestment efficiency
- Earnings Analysis — beats/misses, guidance vs actuals, transcript highlights
- Competitive Positioning — market share, pricing power, peer benchmarks
- Industry Context — TAM, sector tailwinds/headwinds, regulatory backdrop

**API endpoint:** GET /api/v1/research/AHCO/fundamental

## Navigation

- Overview: /stocks/AHCO
- Financials (this page): /stocks/AHCO/financials
- Thesis: /stocks/AHCO/thesis
- Investment Memo: /stocks/AHCO/memo
- Coverage universe: /stocks